Collectively, these data demonstrate that IL21-anti-HSA and anti-PD-1 mAb synergistically enhance a tumor site–focused CD4+ T cell–mediated antitumor immune response through promoting the hyperactivated/exhausted CD4+ T-cell subtype and CD4+ T-cell clonal expansion. Here, PDCD1 is linked to neoplasm.